Diagnostic and Curative Evaluation Value of ProGRP and NSE in Small Cell Lung Carcinoma
10.3969/j.issn.1006-5725.2016.05.020
- VernacularTitle:ProGRP和NSE对小细胞肺癌的诊断及疗效评估的价值
- Author:
Dejing LI
;
Guolan NING
;
Zhaofei LIU
;
Run ZHANG
;
Dianming LI
- Publication Type:Journal Article
- Keywords:
Small cell lung carcinoma;
Pro-gastrin-releasing peptid;
Neuron-specific enolase;
Tu-mor markers
- From:
The Journal of Practical Medicine
2016;32(5):754-758
- CountryChina
- Language:Chinese
-
Abstract:
Obejective To explore the diagnostic and curative evaluation value of gastrin-releasing pep-tide precursor (ProGRP) and neuron specific enolization enzyme (NSE) in small cell lung cancer (SCLC). Methods Sixty SCLC patients, sixty non-small cell lung cancer (NSCLC) patients and forty patients with be-nign pulmonary disease were collected fromJanuary 2014 to October 2015. The levels of serum ProGRP and NSE in all patients were determined by ELISA method and radioimmunoassay respectively then the clinical value of ProGRP and NSE on SCLC was evaluated. Results The levels of ProGRP and NSE in SCLC group were signif-icantly higher than those in NSCLC group and those in lung benign disease group (P < 0.05). The levels of Pro-GRP and NSE in extensive stage were higher than those in limited stage in SCLC group (P < 0.05). The bound-ary value of SCLC through ProGRP identified through ROC curve was 64.68 pg/mL. The diagnostic sensitivity , specific degree and Youdenindex of ProGRP in SCLC were 86.7%, 97.5% and 0.842 respectively, which were significantly higher than NSE (P < 0.05). After 2 cycles of chemotherapy, serum ProGRP in SCLC disease con-trol groupwere significantly decreased(P < 0.05) but on difference of serum ProGRP was found in SCLC progres-siongroup (P > 0.05). Conclusion ProGRP and NSE can be used as markers for the diagnostic and curative evaluation of SCLC. And ProGRP has higher sensitivity and specificity than NSE and can be promoted in clinic.
